National Institute of Allergy and Infectious Diseases Cancellation of Meeting, 50680 [2014-20057]
Download as PDF
<![CDATA[
50680
Federal Register / Vol. 79, No. 164 / Monday, August 25, 2014 / Notices
emcdonald on DSK67QTVN1PROD with NOTICES
status/Pages/status.aspx. The NIH is
required by the BPCA to update the
priority list every three years. This
publication serves as an update to the
BPCA priority list of needs in pediatric
therapeutics.
The Obstetric and Pediatric
Pharmacology and Therapeutics Branch
of the NICHD developed a prioritization
process for the determination of the
needs in pediatric therapeutics. There
are two main phases in this process.
Phase I of the prioritization process
entails identifying therapeutic areas,
which are general categories of
conditions, diseases, settings of care, or
populations with multiple therapeutic
needs. The NICHD solicits input from
experts in the pediatric research, general
pediatric and subspecialty care, and
patient advocacy groups to determine
these therapeutic areas that need further
study. At the beginning of every year,
the NICHD revisits the current list of
needs in pediatric therapeutics,
prioritizes three therapeutic areas of
interest for that calendar year, and
develops working groups in the
prioritized areas. Recommendations
from the therapeutic area working
groups are then presented to the NICHD
and the FDA at the end of the calendar
year at the Institute’s annual BPCA
meeting. Previous meeting minutes can
be found on the BPCA Web site:
https://bpca.nichd.nih.gov/prioritization/
meetings/Pages/index.aspx.
Phase II of the prioritization process
entails an extensive review and ranking
of all nominations received based on
key criteria for prioritization, such as
relevance, label gaps, affected
population, and feasibility. Please visit
the BPCA Web site for more details:
(https://bpca.nichd.nih.gov/
prioritization/priority_list/Pages/
priority_list.aspx).
Below is an updated list of
therapeutic areas and drugs that have
been prioritized for study since the
inception of the BPCA and a summary
of the NICHD’s plans and progress in all
of these areas to date. The NICHD
welcomes input from the pediatric
medical community on additional gaps
in pediatric therapeutics for future
consideration. All nominations should
be submitted to Dr. Perdita TaylorZapata (contact information below).
Priority List of Needs in Pediatric
Therapeutics 2014
In accordance with the BPCA
legislation, the list outlines priority
needs in pediatric therapeutics for
multiple therapeutic areas listed below.
The complete list can be found on the
BPCA Web site at the following address:
https://bpca.nichd.nih.gov.
VerDate Mar<15>2010
17:31 Aug 22, 2014
Jkt 232001
D Table 1: Infectious Disease Priorities
D Table 2: Cardiovascular Disease
Priorities
D Table 3: Respiratory Disease Priorities
D Table 4: Intensive Care Priorities
D Table 5: Bio-Defense Research
Priorities
D Table 6: Pediatric Cancer Priorities
D Table 7: Psychiatric Disorder Priorities
D Table 8: Neurological Disease
Priorities
D Table 9: Neonatal Research Priorities
D Table 10: Adolescent Research
Priorities
D Table 11: Hematologic Disease
Priorities
D Table 12: Endocrine Disease Priorities
and Diseases With Limited Alternative
Therapies
D Table 13: Dermatologic Disease
Priorities
D Table 14: Gastrointestinal Disease
Priorities
D Table 15: Renal Disease Priorities
D Table 16: Rheumatologic Disease
Priorities
D Table 17: Special Considerations
We would like for you to save the date
of December 10, 2014, for our annual
BPCA stakeholders meeting. The
meeting will be held at the Natcher
Auditorium on the NIH campus in
Bethesda, Maryland, and will be
streamed live via videocast for all nonlocal attendees.
FOR FURTHER INFORMATION CONTACT: Dr.
Perdita Taylor-Zapata via email at
taylorpe@mail.nih.gov; by phone at
301–496–9584; or by fax at 301–480–
2897.
Dated: August 18, 2014.
Francis S. Collins,
Director, National Institutes of Health.
[FR Doc. 2014–20156 Filed 8–22–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases Cancellation of
Meeting
Notice is hereby given of the
cancellation of the National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, September 10, 2014,
10:00 a.m. to September 10, 2014, 12:00
p.m., National Institutes of Health,
6700B Rockledge Drive, Room 3124,
Bethesda, MD 20817 which was
published in the Federal Register on
August 15, 2014, 79FR48173.
The Review Committee will not meet
because the application was withdrawn.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Dated: August 19, 2014.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–20057 Filed 8–22–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Ancillary Studies to
the NIDDK IBDGC.
Date: October 16, 2014.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Dianne Camp, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 756, 6707, Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–7682,
campd@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases,
Special Emphasis Panel, Small Grants for
New Investigators to Promote Diversity.
Date: October 30, 2014.
Time: 12:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Barbara A. Woynarowska,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 754, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
402–7172, woynarowskab@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
E:\FR\FM\25AUN1.SGM
25AUN1
]]>Agencies
[Federal Register Volume 79, Number 164 (Monday, August 25, 2014)]
[Notices]
[Page 50680]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-20057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases
Cancellation of Meeting
Notice is hereby given of the cancellation of the National
Institute of Allergy and Infectious Diseases Special Emphasis Panel,
September 10, 2014, 10:00 a.m. to September 10, 2014, 12:00 p.m.,
National Institutes of Health, 6700B Rockledge Drive, Room 3124,
Bethesda, MD 20817 which was published in the Federal Register on
August 15, 2014, 79FR48173.
The Review Committee will not meet because the application was
withdrawn.
Dated: August 19, 2014.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-20057 Filed 8-22-14; 8:45 am]
BILLING CODE 4140-01-P
